drugset / Trial / NCT05536349
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Phase 2
Recruiting
60 enrolled
M.D. Anderson Cancer Center
Loxo Oncology, Inc. · collabThe Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received treatment.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2028-04-25
- Completion
- 2028-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Pirtobrutinib | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |
| Background | Allopurinol | Small molecule | — | Oral |
| Background | Valacyclovir | Unknown | — | Oral |